Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Endocrinology | Family Medicine
 Disease Category: Ovarian Cancer
Location: United States, NY

Trial Information

Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-line and Second-line Therapy

The purpose of this study is to determine whether paclitaxel will cause malignant stromal tumor of the ovary will cause the cancer to completely disappear at all sites and all places where cancer has been detected.

Inclusion criteria:

  • Histologically confirmed ovarian stromal cancer not amenable to surgery
  • Recurrent disease after no more than 1 prior chemotherapy regimen
  • Tumor must be at least 1 cm in diameter
  • ECOG performance status of 0-2
  • WBC at lease 3,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Bilirubin no greater that 1.5 times normal
  • SGOT no greater than 3 times normal
  • Creatinine no greater than 2.0 mg/dL

Exclusion criteria:

  • Pregnancy
  • Other prior invasive malignancy in the past 5 years except non-melanoma skin cancer

Mark Einstein, MD, Principal Investigator/ Lorraine Centrilla, RN, Research Nurse
Einstein-Montefiore Institute for Clinical & Translational Research
Montefiore Medical Center
1695 Eastchester Road
Bronx, NY 10461
Phone: 718-405-8082
Email: meinstei@montefiore.org

View Map

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.